In this update, Matthew reports on how 2019 revenues have already surpassed 2018 revenues across multiple divisions as well as how its potential acquisition could lead to engagements with large scale investors. This progress has motivated Med-X Management to prepare the company accordingly, as they meet with the potential sponsors to list the company.
Our largest Over The Counter or “OTC” Pharmacy distributor Cardinal Health / RGH just placed an order to continue to distribute the Thermal-Aid product line throughout “OTC” pharmacies which are performing well and selling-through. We anticipate these orders to continue to increase in frequency and volume.
This kind of traction coupled with our direct to consumer boost through Amazon, is forcing us to quickly ramp up our production for this line as PO’s from our distributors continue to get larger and inventory requirements from Amazon Fulfillment continue to increase and seemingly are snowballing. We need to be ready for 2020 because at these rates it is going to be a busy start to the year.
We feel strongly that with all of this increased visibility and with these high sell-through rates it is only a matter of time before the bigger “OTC” retail players jump on board and begin to load the products as well, so we need to be ready!
Conversations have also continued to ramp up with many overseas pest control operation distributors. We are in talks with companies from Canada, Mexico, Indonesia, Nicaragua, Brazil, Peru, Australia, Saudi Arabia, Dubai, Bahrain, South Africa, United Kingdom, New Zealand, Malaysia, the Philippines, and South Korea. Governments in these countries continue to tighten regulations on the use of pesticides and these distributors are scrambling to get new products in place that will pass their toxicity and environmental impact requirements.
The importation of pesticides into foreign countries requires the company to comply with each countries stringent regulatory red tape. We are working to have the Nature-Cide products fully scrutinized and registered in all of these countries. Once the studies are done we will be able to register our products on an individual basis with each country, all of which have their own requirements and processes that require the above-mentioned testing to be completed. This is an incredibly important time for our company to buckle down and invest as much of our resources as possible in getting the Nature-Cide products positioned accordingly. Once this is accomplished, Nature-Cide products and protocols could very well end up leading the all-natural global pest control markets.
The company is also in the final stages of an acquisition of a pest control service company that is doing over $1M annually in service revenue.
With this acquisition, our plan is to significantly increase revenue in 2020 compared to 2019 starting in Q1. We are all hopeful and waiting patiently for the legal teams to finalize agreements, so the company can make the acquisition official. We are also hopeful that several other acquisition targets will fall into line once the first transaction is complete, and word continues to spread that we are actively acquiring like-minded pest control companies.
The revenue growth and acquisition plans have various large scale investment funds watching the company very closely, and we are excited to have the opportunity to present our work accordingly. This said we are meeting with an interested sponsor in the coming days to discuss the process of a 15c2-11 filing which is the first step in the potential listing of the company. The goal is to organize and engage with the perfect financial partner to support our growth and acquisition plans, then expand further if and when we list in a public marketplace.
The team is dedicated to working harder than ever in the final weeks of 2019, in order to make sure the company continues to grow and we begin 2020 in the best shape we have ever been in. We are all excited to see what the future holds.
Matthew is available to discuss the growth of the company one-on-one, so don't hesitate to reach out and schedule an appointment.
Thank you for all of your continued support.
Nick Phillips
Med-X Team
DISCLAIMER AND FORWARD-LOOKING STATEMENTS
The securities offered by Med-X, Inc. hereby are highly speculative. Investing in shares of MED-X, INC. involves significant risk. This investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment could be illiquid for an indefinite period of time. No public market currently exists for the securities and if and when a public market develops following this offering it may not continue. You should read the NEW Offering Circular as well as all Securities Exchange Commission filings before making any investment in the Company.
This release may contain forward-looking statements regarding projected business performance, operating results, financial condition and other aspects of the company, expressed by such language as "expected," "anticipated," "projected" and "forecasted." Please be advised that such statements are estimates only and there is no assurance that the results stated or implied by forward-looking statements will actually be realized by the company. Forward-looking statements may be based on management assumptions that prove to be wrong. The company and its business are subject to substantial risks and potential events beyond its control that would cause material differences between predicted results and actual results, including the company incurring operating losses and experiencing unexpected material adverse events.